Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in Growth Strategy
Macro·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Teva Pharmaceuticals has commenced trading its ordinary shares directly on the New York Stock Exchange (NYSE), a significant step in its growth strategy. This transition from American Depositary Receipts (ADRs) to direct trading is expected to enhance investor engagement and market presence.
In an interview, Teva CEO Richard Francis explained the timing of this change and its implications for investors. He emphasized that this move aligns with the company's strategic goals and aims to provide a more streamlined experience for shareholders.
Teva PharmaceuticalsRichard Francis
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy”
SEC Filing — Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy“Teva Pharmaceuticals President & CEO Richard Francis, discusses why Teva chose to make the change now and what will be different for investors as the shares move from ADRs to direct NYSE trading.”
Bloomberg — Teva CEO on Shares Trading Directly on the NYSE